Department of Oncology, Laboratory of Cancer Biology, Medical Sciences Division, University of Oxford, Oxford, UK.
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences University of Oxford, Nuffield Orthopaedic Centre, Windmill Road, Oxford, UK.
Oncogene. 2014 Jul 3;33(27):3594-603. doi: 10.1038/onc.2013.316. Epub 2013 Aug 12.
Transcription factor E2F-1 and its interaction with pRb provide a key point of control in cell proliferation. E2F-1 participates in both cell cycle progression and apoptosis, and in cells exists with a DP dimerization partner protein, the most prominent being DP-1. By mining the tumor tissue and cancer cell line encyclopedia genomic databases, we identified the first somatic mutations in the DP-1 gene and describe 53 distinct mutation events here. The mutations are mostly missense mutations, but also include nonsense and frame-shift mutations that result in truncated DP-1 derivatives. Mutation occurs throughout the DP-1 gene but generally leaves protein dimerization activity intact. This allows the mutant derivatives to affect the properties of the E2F-1/DP-1 heterodimer through a transdominant mechanism, which changes the DNA binding, transcriptional activation and pRb-binding properties of the heterodimer. In particular, many DP-1 mutants were found to impair E2F-1-dependent apoptosis. Our results establish that somatic mutations in DP-1 uncouple normal control of the E2F pathway, and thus define a new mechanism that could contribute to aberrant proliferation in tumor cells.
转录因子 E2F-1 及其与 pRb 的相互作用为细胞增殖提供了一个关键控制点。E2F-1 参与细胞周期进展和细胞凋亡,并且与 DP 二聚化伴侣蛋白存在于细胞中,其中最突出的是 DP-1。通过挖掘肿瘤组织和癌细胞系基因组数据库,我们在 DP-1 基因中首次鉴定出体细胞突变,并在此处描述了 53 个不同的突变事件。这些突变大多是错义突变,但也包括无义突变和移码突变,导致 DP-1 截短衍生物。突变发生在 DP-1 基因的整个区域,但通常保持蛋白二聚化活性完整。这使得突变衍生物能够通过显性突变机制影响 E2F-1/DP-1 异二聚体的性质,从而改变异二聚体的 DNA 结合、转录激活和 pRb 结合特性。特别是,许多 DP-1 突变体被发现会抑制 E2F-1 依赖性细胞凋亡。我们的研究结果表明,DP-1 的体细胞突变使 E2F 途径的正常调控脱耦,从而定义了一种可能导致肿瘤细胞异常增殖的新机制。